A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2001
11/08/2001	WO2001082938A2 Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate
11/08/2001	WO2001082928A1 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
11/08/2001	WO2001082924A1 Phosphate transport inhibitors
11/08/2001	WO2001082923A1 Estrogen receptor modulators
11/08/2001	WO2001082918A2 Method for the prevention of apoptosis
11/08/2001	WO2001082897A2 Liposome drug delivery
11/08/2001	WO2001082888A1 Lipochroman-6 as no-synthase inhibitor and uses
11/08/2001	WO2001082887A1 Plant extract of the species vitis vinifera as no-synthase inhibitor and uses
11/08/2001	WO2001082870A2 A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
11/08/2001	WO2001082858A2 Novel compounds for the treatment of inflammatory and cardiovascular diseases
11/08/2001	WO2001082720A1 Pet food composition for reducing inflammatory response in cats
11/08/2001	WO2001082699A1 A gene therapy system and method using alpha-msh and its derivatives
11/08/2001	WO2001049657A8 2-`3-amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors
11/08/2001	WO2001044242A9 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001040180A3 N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents
11/08/2001	WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001	WO2001038564A3 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
11/08/2001	WO2001037780A8 Urotensin-ii analogs
11/08/2001	WO2001036489A3 Erythropoietin forms with improved properties
11/08/2001	WO2001034617A3 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
11/08/2001	WO2001032128A3 Human chemokine beta-13
11/08/2001	WO2001030383A3 Medicament in order to induce tolerance
11/08/2001	WO2001029012A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	WO2001029011A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	WO2001028574A3 Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain
11/08/2001	WO2001018035A3 Muc-1 derived peptides
11/08/2001	WO2001010846A3 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
11/08/2001	WO2001008707A3 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/08/2001	WO2001002551A3 Virus like particles, preparation and use in screening and functional genomics
11/08/2001	WO2000076556A9 High dose radionuclide complexes for bone marrow suppression
11/08/2001	WO2000069897A3 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
11/08/2001	WO2000017133A3 Lta4 hydrolase inhibitors
11/08/2001	US20010039441 Apparatuses and processes for whole-body hyperthermia
11/08/2001	US20010039438 Method for treating neovascularization
11/08/2001	US20010039289 Antagonists; especially sodium salts
11/08/2001	US20010039285 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/08/2001	US20010039284 Acetylcholine enhancers
11/08/2001	US20010039282 Desloratadine as non-sedating antihistamine, decongestant
11/08/2001	US20010039280 Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists
11/08/2001	US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001	US20010039273 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
11/08/2001	US20010039271 For treatment of male erectile dysfunction, female sexual dysfunction
11/08/2001	US20010039265 Administering to the subject an effective amount of a polyglycoside or a salt thereof, wherein the polyglycoside comprises a chain of glycosidic residues substituted with an anionic substituent
11/08/2001	US20010039256 Administering to subject a polypeptide derived from soluble receptor for advanced glycation end product
11/08/2001	US20010038843 Immunogenic polypeptide comprising a self Immunoglobin E (IgE) portion and a non-self IgE portion, to induce an anti-self IgE response in a mammal; treating diseases such as allergies
11/08/2001	US20010038830 N,O-amidomalonate platinum complexes
11/08/2001	EP1144348A3 Lta 4? hydrolase inhibitors
11/08/2001	DE10019755A1 New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes
11/08/2001	CA2418748A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2409689A1 Combination therapy of respiratory diseases using antibodies
11/08/2001	CA2408105A1 Novel proteases
11/08/2001	CA2408011A1 Splice-region antisense composition and method
11/08/2001	CA2407970A1 A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
11/08/2001	CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	CA2407956A1 Modified peptides as therapeutic agents
11/08/2001	CA2407808A1 Cyclipostins, process for their preparation and use thereof
11/08/2001	CA2407799A1 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001	CA2407796A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
11/08/2001	CA2407700A1 Compositions and methods for inducing activation of dendritic cells
11/08/2001	CA2407597A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001	CA2407587A1 Ppar.gamma. modulators
11/08/2001	CA2407535A1 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
11/08/2001	CA2407435A1 Rna metabolism proteins
11/08/2001	CA2407426A1 Immunoadhesin for the prevention of rhinovirus infection
11/08/2001	CA2407418A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001	CA2407399A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/08/2001	CA2407334A1 Lipochroman-6 as no-synthase inhibitor and uses
11/08/2001	CA2407311A1 Plant extract of the species vitis vinifera as no-synthase inhibitor and uses
11/08/2001	CA2407294A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001	CA2407292A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
11/08/2001	CA2407219A1 Pain signaling molecules
11/08/2001	CA2407189A1 New gamma selective retinoids
11/08/2001	CA2407136A1 Treatment of conditions of the central nervous system using mycobacteria
11/08/2001	CA2406999A1 Gene and sequence variation associated with sensing carbohydrate compounds and other sweeteners
11/08/2001	CA2406755A1 A gene therapy system and method using alpha-msh and its derivatives
11/08/2001	CA2405832A1 P-(sulfonyl)aryl and heteroaryls
11/08/2001	CA2405611A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	CA2377629A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/07/2001	EP1152056A1 Method for modifying genetic characteristics of an organism
11/07/2001	EP1152055A1 ADAMTS polypeptides, nucleic acids encoding them, and uses therof
11/07/2001	EP1152009A1 Novel nucleosides and oligonucleotide analogues
11/07/2001	EP1152004A1 Phosphonic acid derivatives having carboxypeptidase b inhibitory activity
11/07/2001	EP1152002A1 Pyrrole derivatives and cell death inhibitors
11/07/2001	EP1151995A1 Process for the preparation of the mesylate salt trihydrate of 1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-Phenylpiperidin-1-YL)-1-Propanol
11/07/2001	EP1151131A1 Process for the preparation of pseudomonic acid a antibiotic by microbiological method
11/07/2001	EP1151124A1 Gene repair involving in vivo excision of targeting dna
11/07/2001	EP1151113A2 Human peptidases
11/07/2001	EP1151109A1 Fucosyl transferase gene
11/07/2001	EP1151101A1 Prostacyclin-stimulating factor-2
11/07/2001	EP1151100A1 Tau-conotoxin peptides
11/07/2001	EP1151091A1 Improved helper dependent vector system for gene therapy
11/07/2001	EP1151088A1 Improved phytases
11/07/2001	EP1151083A1 Nitroreductase enzymes
11/07/2001	EP1151012A1 Rhamm antagonist antibodies
11/07/2001	EP1151008A1 Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
11/07/2001	EP1151004A1 Method for producing il-1ra, a therapeutically active protein from body fluids
11/07/2001	EP1151002A1 Antibodies specific to kdr and uses thereof

1 ... 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 ... 1564